Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease

NCT00635427 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT00635427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00635427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease
Lead sponsor
Shire
Phase
Phase 3
Overall status
Completed
Start date
March 13, 2008
Completion date
December 28, 2012
Enrollment
95 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

gaucher disease, type 1